26,117 stock options awarded to Bionano Genomics (BNGO) counsel

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported a new equity award for its General Counsel, Jonathan V. Dixon. On 02/02/2026, he received a stock option to buy 26,117 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, so it becomes fully vested and exercisable on the four-year anniversary of that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dixon Jonathan V.

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.27	02/02/2026		A		26,117		(1)	02/01/2036	Common Stock	26,117	$0	26,117	D

Explanation of Responses:

1. Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bionano Genomics (BNGO) report for its General Counsel?

Bionano Genomics reported that its General Counsel, Jonathan V. Dixon, received a stock option grant for 26,117 shares of common stock. This derivative award was reported on 02/02/2026 as an acquisition of options, held directly after the transaction.

What is the exercise price of the 26,117 stock options granted at Bionano Genomics (BNGO)?

The granted stock option allows the holder to buy 26,117 shares of Bionano Genomics common stock at an exercise price of $1.27 per share. This price is fixed in the award and applies throughout the option’s term until expiration.

How do the new Bionano Genomics (BNGO) options vest for the General Counsel?

The option vests monthly over 48 months, starting on the one-month anniversary of the vesting commencement date. As a result, the award becomes fully vested and exercisable on the four-year anniversary of that vesting commencement date, assuming continuous service.

When do the newly granted Bionano Genomics (BNGO) options expire?

The stock option granted to the General Counsel expires on 02/01/2036. Until that expiration date, vested portions of the option can be exercised at the stated $1.27 per share exercise price, subject to the company’s applicable equity plan and award terms.

How many Bionano Genomics (BNGO) derivative securities does the General Counsel hold after this grant?

Following the reported transaction, the General Counsel beneficially owns 26,117 derivative securities in the form of stock options. These options are held directly and correspond to 26,117 underlying shares of Bionano Genomics common stock, subject to the vesting schedule.

What role does the reporting person hold at Bionano Genomics (BNGO)?

The reporting person on this Form 4, Jonathan V. Dixon, serves as an officer of Bionano Genomics with the title General Counsel. He is not listed as a director or 10% owner in connection with this specific insider transaction report.